萨克拉门托生物科技公司Lunai Bioworks将从纳斯达克退市
位于加利福尼亚州萨克拉门托县的生物科技公司 Lunai Bioworks 10 月 22 日宣布，将自愿从纳斯达克退市并注销注册。该公司 10 月 21 日收到纳斯达克上市资格部门来函，称其已不符合上市规则第 5550(b)(1) 条关于股东权益最低 250 万美元的要求：公司在截至 2026 年 6 月 30 日财年的年报中报告股东权益为负 902 万余美元，也不符合市值或净收入的替代标准。因公司处于强制听证监督之下，纳斯达克工作人员已决定将其证券摘牌，其普通股交易预计于 10 月 30 日开市时暂停。
公司表示不会申请听证，董事会已于 10 月 22 日批准按《证券交易法》规则自愿退市，理由是工作人员的决定与公司财务状况决定了继续上市与履行证监会报告义务的成本不再合理。公司计划于 11 月 2 日前后向美国证券交易委员会提交 25 号表格，退市预计于 11 月 12 日前后生效，其后将提交 15 号表格以暂停报告义务。
Sacramento biotech Lunai Bioworks to voluntarily delist from Nasdaq
SACRAMENTO, California — Lunai Bioworks Inc., a biotech company based in Sacramento, Sacramento County, California, announced on October 22 that it will voluntarily delist from Nasdaq and deregister. On October 21, the company received a letter from Nasdaq's Listing Qualifications Department stating that it no longer complies with Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million: the company reported a stockholders' deficit of about $9.02 million in its annual report for the fiscal year ended June 30, 2026, and does not meet the alternative market-value or net-income standards. Because the company is subject to a mandatory Hearings Panel Monitor, Nasdaq staff determined to delist its securities, and trading is expected to be suspended at the opening of business on October 30.
The company will not request a hearing. Its board approved the voluntary withdrawal on October 22, concluding that, given the staff determination and the company's financial condition, the cost of continued listing and SEC reporting is not justified. Lunai intends to file a Form 25 with the SEC on or about November 2, expects the delisting to become effective on or about November 12, and then intends to file a Form 15 to suspend its reporting obligations.
来源：GSM·美国（原文链接）
图片来源：萨克拉门托塔桥资料照片。图片：Michael Grindstaff，公有领域，经Wikimedia Commons。 / The Tower Bridge in Sacramento, file photo. Photo: Michael Grindstaff, public domain, via Wikimedia Commons.
